N-Acetyl Cysteine in the Prevention of Contrast Induced Nephropathy in Cirrhosis of Liver-NEPHRO Trial
NCT ID: NCT03759158
Last Updated: 2019-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2018-12-01
2019-01-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NASPI: N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization
NCT00356954
The Acetylcysteine for Contrast-Induced Nephropathy Trial
NCT00736866
Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy
NCT00939913
N-Acetyl Cystein and Contrast Nephropathy
NCT01820195
Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
NCT00558142
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NAC Arm
NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
N-Acetyl Cysteine
NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
Placebo
Placebo Oral Tablet
Placebo Oral Tablet twice daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
N-Acetyl Cysteine
NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
Placebo Oral Tablet
Placebo Oral Tablet twice daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal kidney parameters (Creatinine below \<1 ,Creatinine clearance \>60)
* Cirrhosis of liver
* eGFR\>60ml/min
Exclusion Criteria
* H/o anaphylaxis to contrast
* Prior h/o AKI
* GFR\<60 ML/MIN
* Prior H/o TACE/HVPG /Contrast ECHO in the last 4 weeks
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of Liver and Biliary Sciences, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ILBS-Cirrhosis-19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.